SuperGen Inc: Premium Company Profile

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 2007-12-24

Order Online Now

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

SuperGen is a pharmaceutical company dedicated to the discovery, development and commercialization of therapies to treat patients with cancer. Historically, the company has acquired products that were approved for market or for clinical investigation and applied additional developmental effort to expand sales or advance these products clinically towards potential approval for marketing.


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    CLIMB (Computational Lead Identification Modeling Biology) is SuperGen's approach to small molecule drug discovery, which merges rapid screening of compound libraries with computational chemistry and systems biology techniques to identify drug leads that bind to target proteins.

    Three compounds have been the primary focus of SuperGen's efforts: Dacogen for injection, Orathecin capsules and Nipent (pentostatin for injection). In 2006, Dacogen received approval for marketing in the US, Orathecin was withdrawn from the regulatory review process, Nipent and commercial infrastructure was sold to Mayne Pharma (Hospira).

    SuperGen's pipeline includes MP470 Tyrosine Kinase Inhibitor/Rad 51 Suppressor and MP529 Aurora A Kinase Inhibitor, which are in preclinical stage of development. SuperGen has derived its revenues from product sales of Nipent and Surface Safe products, royalty from Dacogen sales by MGI Pharma and license fees.


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: supergen inc pipeline company details contact competition dacogen mp529 hospira

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.